摘要
目的:观察重组人血管内皮抑素(YH-16)联合长春瑞滨和顺铂(NP)治疗Ⅲb-Ⅳ期非小细胞肺癌(non-small cell carcinoma,NSCLC)的近期临床疗效及安全性。评价治疗前、后外周血癌胚抗原(carcino-embryonic antigen,CEA)在NSCLC治疗中的价值。方法:应用YH-16联合NP方案治疗晚期NSCLC共34例,统计临床有效率、临床收益率、生存质量并比较治疗前后外周血CEA水平。结果:34例患者临床有效率为14.71%(5/34),临床收益率为70.59%(24/34),治疗后生存质量明显提高且差异具有统计学意义(P<0.05)。34例患者血清CEA水平从治疗前(57.30±4.93)ng/ml下降到第2周期治疗后(15.64±7.50)ng/ml,两组CEA水平相比差异有统计学意义(P<0.05)。结论:YH-16联合NP方案治疗晚期NSCLC是合理、安全、有效的。CEA可能是一个预测YH-16联合NP方案治疗NSCLC疗效的标志物。
Objective： To observe the recent clinical efficacy and safety of recombinant human endostatin （YH-16） combined with vinorelbine and cisplatin （NP） in the treatment of lll b-IV nonsmall cell lung cancer （NSCLC） and evaluate the value of carcino-embryonic antigen （CEA） in peripheral blood before and after treatment of NSCLC. Methods： 34 patients with advanced NSCLC were treated by YH-16 plus NP proposal. The clinical efficiency before and after treat- ment, clinical benefit rate, quality of life and serum CEA levels were compared. Results： clinical efficiency rate of 34 cases of patients was 14.71% （5/34）, clinical benefit rate was 70.59% （24/34） , quality of life improved significantly after treatment and the difference was statistically significant （P 〈 0.05 ）. Serum CEA level before treatment with （57.30± 4.93 ） ng/ml decreased to （15.64 ±7.50） ng/ml in the second cycle after treatment, the difference was statistically significant （P 〈 0. 05）. Conclusion： YH-16 combined with NP regimen for advanced NSCLC is reasonable, safe and effective. CEA may be useful in predicting the efficacy of the combined treatment.
出处
《河南医学研究》
CAS
2014年第1期7-10,共4页
Henan Medical Research
基金
河南省卫生厅科技攻关项目(200803123)
河南省卫生厅科技攻关项目(082300450060)
关键词
重组人血管内皮抑素
长春瑞滨
顺铂
癌胚抗原
非小细胞肺癌
疗效
recombinant human endostatin
vinorelbine
cisplatin
carcino-embryonic antigen
non-small cell lung cancer
efficacy
